tbuckley/cabot-search huggingface dataset:
Reference Directories
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Intermediate monocytes induced by IFN-γ inhibit cancer metastasis by promoting NK cell activation through FOXO1 and interleukin-27
Authors: Rikang Wang, Weili Bao, Mouli Pal, Yunfeng Liu, Karina Yazdanbakhsh, Hui Zhong
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background Circulating monocytes are functionally heterogeneous and can be divided into classical (CMo), intermediate (IMo), and non-CMo/patrolling monocyte (PMo) subsets. CMo can differentiate into PMo through IMo. PMos have been shown to inhibit cancer metastasis but the role of IMo is unclear. To date, no strategy has been developed to inhibit cancer metastasis through enhancing PMo/IMo differentiation. Methods We screened multiple inflammatory cytokines/chemokines activity of modulating PMo/IMo associated cell markers expression using human monocyte in vitro culture system. We tested our candidate cytokine activity in vivo using multiple mice models. We identified critical key factors and cytokines for our candidate cytokine activity by using gene-knockout mice and neutralization antibodies. Results We identified IFN-γ as a candidate inflammatory cytokine in the regulation of human IMo/PMo marker expression. Our in vivo data demonstrated that IMo expansion was induced by short-term (3 days) IFN-γ treatment through increasing CMo-IMo differentiation and blocking IMo-PMo differentiation. The IMo induced by IFN-γ (IFN-IMo), but not IFN-γ activated CMo (IFN-CMo), inhibited cancer metastasis by 90%. Surprizing, the effect of IFN-γ is greater in PMo deficiency mice, indicating the effect of IFN-IMo is not mediated through further differentiation into PMo. We also found that IFN-IMos induced by short-term IFN-γ treatment robustly boosted NK cell expansion for threefold and promoted NK differentiation and function through IL-27 and CXCL9. Furthermore, we identified that FOXO1, a key molecule controlling cellular energy metabolism, mediated the effect of IFN-γ induced IL-27 expression, and that NR4A1, a key molecule controlling PMo differentiation and inhibiting cancer metastasis, inhibited the pro-NK cell and anti-metastasis activity of IFN-IMo by suppressing CXCL9 expression. Conclusions We have discovered the antimetastasis and pro-NK cell activity of IFN-IMo, identified FOXO1 as a key molecule for IFN-γ driven monocyte differentiation and function, and found NR4A1 as an inhibitory molecule for IFN-IMo activity. Our study has not only shown novel mechanisms for a classical antitumor cytokine but also provided potential target for developing superior monocytic cell therapy against cancer metastasis.
Sixteenth Annual Symposium on Fundamental Cancer Research
Journal: JNCI Journal of the National Cancer Institute (1961)

Sixteenth Annual Symposium on Fundamental Cancer Research Get access JNCI: Journal of the National Cancer Institute, Volume 27, Issue 5, November 1961, Page 1224, https://doi.org/10.1093/jnci/27.5.1224 Published: 01 November 1961
Leadless Pacing—Uncertainties Remain About Safety and Efficacy
Authors: Linh Ngo, Russell Denman, Isuru Ranasinghe
Journal: JAMA Cardiology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
P138: WHITE PAPER: ASSESSMENT OF INTERNATIONAL SICKLE CELL DISEASE GUIDELINES IN HIGH-, MIDDLE-, AND LOW-INCOME COUNTRIES
Authors: N Suthar, T Halpern, L Hsu
Journal: HemaSphere (2022)

Sickle cell disease (SCD) is a common genetic condition defined by abnormalities in hemoglobin, an oxygen carrying protein in red blood cells. About 5% of the world’s population carries genes for hemoglobin disorders, with the highest prevalence in countries in Subsaharan Africa (SSA). SCD causes significant morbidity, mortality, and economic burden in the countries and populations affected. Various countries have established national guidelines for SCD management, which serve to standardize care and improve patient outcomes. Ten such guidelines were identified for compilation and analysis in this paper as of summer 2021. Qualitative analysis of the guidelines has identified the priorities of each government and medical institutions’ stance on best practices across high-, middle-, and low-income countries. The analysis identified that care for acute complications of SCD is more frequently endorsed in the guidelines of low-and-middle income countries (LMIC), which also have higher disease burden, over high-income countries (HIC). Chronic preventative care for SCD disease, which is shown to be an evidence-based effective approach to improve patient outcomes, is more frequently recommended in guidelines of HIC over LMIC. Furthermore, national newborn screening guidelines are scarce in the countries with high prevalence rates and adolescent mortality. While most countries recommend screening programs, LMIC have limited recommendations for newborn preventative measures. Incorporation and prioritization of preventive care guidelines in LMIC may serve as a path to inform sustainable nationwide interventions to improve patient outcomes for SCD. Implementation of these guidelines would contribute to preventing acute complications and improving morbidity and mortality for individuals with SCD. In addition, prioritization and inclusion of preventive and chronic care measures in healthcare services may mitigate the economic burden of SCD in LMIC. References 1. Yawn et al. JAMA 2014. 312;10. 2. Piel et al, PLOS Medicine 2013; 10:7 3. Kato et al, Nat Rev Dis Primers 2018; 15:4. 4. Ryan et al. Br J Haematol 2010; 149;1. 5. Alli et al. S Afr Med J 2014; 104;11.
Research Goes Red: Early Experience With a Participant-Centric Registry
Authors: Susan C. Gilchrist, Jennifer L. Hall, Abha Khandelwal, Bertha Hidalgo, Brooke Aggarwal, Claire Kinzy, Pratheek Mallya, Katie Conners, Laura M. Stevens, Heather M. Alger, Laxmi Mehta, Laura Wexler, Jessica L. Mega, Adrian Hernandez, Sharonne N. Hayes, Jennifer H. Mieres, Mariell Jessup, Veronique L. Roger
Journal: Circulation Research (2022)

Cardiovascular disease remains the leading cause of death in women. To address its determinants including persisting cardiovascular risk factors amplified by sex and race inequities, novel personalized approaches are needed grounded in the engagement of participants in research and prevention.
Shifting the Demand for Vaccines: A Review of Strategies
Authors: Neeraj Sood, Tahmina Nasserie, Sushant Joshi, Eran Bendavid
Journal: Annual Review of Public Health (2022)

Vaccines prevent millions of deaths, and yet millions of people die each year from vaccine-preventable diseases. The primary reason for these deaths is that a significant fraction of the population chooses not to vaccinate. Why don't people vaccinate, and what can be done to increase vaccination rates besides providing free and easy access to vaccines? This review presents a conceptual framework, motivated by economic theory, of which factors shift the demand for vaccines. Next, it critically examines the literature on these demand shifters and interventions that target these demand shifters. The review concludes with offering directions for future research and lessons for public health decision making.
T-Cell Subsets as Potential Biomarkers for Hepatobiliary Cancers and Selection of Immunotherapy Regimens as a Treatment Strategy
Authors: Chandan Kumar-Sinha, Vaibhav Sahai
Journal: Journal of the National Comprehensive Cancer Network (2022)

Patients with advanced hepatocellular or biliary cancers have a dismal prognosis with limited efficacy from standard systemic therapies. The benefit of precision medicine has so far been limited to a subset of biliary cancers, including FGFR rearrangements; hotspot mutations in IDH1/2 , BRAF , and BRCA1/2 ; and other rare alterations. In contrast, hepatocellular carcinoma, an inflammation-driven cancer with an immune-infiltrated microenvironment, provides a promising opportunity for immunotherapy, compared with the highly desmoplastic immune desert or excluded stromal microenvironment in biliary cancers. The immune contexture in hepatobiliary cancers is mostly immunosuppressive, protumorigenic, and exhausted, which together with low tumor mutation burden and decreased neoantigens provides challenges for immunotherapy. A better understanding of the spatiotemporal profile of T cells within the tumor microenvironment and the dynamic interplay of immune modulators in the context of standard or experimental therapies is crucial to define additional markers of response and design evidence-based combinatorial regimens. This review considers recent literature in this area and highlights promising leads and emerging trends.
Journal of Experimental Medicine, New York
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Staphylococcic Infections Treated with Fusidic Acid in Nurses
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
<i>γ</i>‐Fe<sub>2</sub>O<sub>3</sub> Loading Mitoxantrone and Glucose Oxidase for pH‐Responsive Chemo/Chemodynamic/Photothermal Synergistic Cancer Therapy
Authors: Zhihao Zhong, Chao Liu, Yatao Xu, Weili Si, Wenjun Wang, Liping Zhong, Yongxiang Zhao, Xiaochen Dong
Journal: Advanced Healthcare Materials (2022)

Traditional cancer therapy is limited by poor prognosis and risk of recurrence. Emerging therapies offer alternatives to these problems. In addition, synergistic therapy can combine the advantages of multiple therapies to eliminate cancer cells while attenuating damage to normal tissues. Herein, a theranostic nanoplatform based on the chemotherapeutic drug mitoxantrone (MTO) and glucose oxidase (GOx) co-loaded γ-Fe2 O3 nanoparticles (MTO-GOx@γ-Fe2 O3 NPs) is designed and prepared to realize photoacoustic imaging-guided chemo/chemodynamic/photothermal (CT/CDT/PTT) synergistic cancer therapy. With a particle size of about 86.2 nm, the synthesized MTO-GOx@γ-Fe2 O3 NPs can selectively accumulate at tumor sites by enhanced permeability and retention (EPR) effects. After entering cancer cells by endocytosis, MTO-GOx@γ-Fe2 O3 NPs decompose into Fe3+ ions and release cargo because of their pH-responsive characteristic. As a Food and Drug Administration (FDA)-approved chemotherapy drug, MTO shows strong DNA disruption ability and satisfying photothermal conversion ability under laser irradiation for photothermal therapy. Simultaneously, GOx catalyzes the decomposition of glucose and generates hydrogen peroxide (H2 O2 ) to enhance the chemodynamic therapy efficiency. In vitro and in vivo experiments reveal that MTO-GOx@γ-Fe2 O3 NPs possess a significant synergistic therapeutic effect in cancer treatment.
TCR-sequencing in cancer and autoimmunity: barcodes and beyond
Authors: Kristen E Pauken, Kaitlyn A Lagattuta, Benjamin Y Lu, Liliana E Lucca, Adil I Daud, David A Hafler, Harriet M Kluger, Soumya Raychaudhuri, Arlene H Sharpe
Journal: Trends in Immunology (2022)
Ebola: Europe–Africa research collaborations
Authors: Peter William Horby, Hubert Endtz, Jean-Jacques Muyembe-Tamfum, Johan van Griensven, Sahr Gevao, Herman Goossens, Denis Malvy, Niankoye Yves Haba, Yazdan Yazdanpanah, Piero Olliaro, Malcolm G Semple, Menno de Jong, Alexandre Delamou, Trudie Lang, Gail Carson, Stephen B Kennedy
Journal: The Lancet Infectious Diseases (2015)
Materials
Authors: M. S. Simon
Journal: JNCI Journal of the National Cancer Institute (1992)

Materials Get access Michael S. Simon Michael S. Simon Division of Hematology and Oncology Wayne State University School of Medicine3990 John R. Street Detroit, MI 48201 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 12, 17 June 1992, Page 988, https://doi.org/10.1093/jnci/84.12.988-b Published: 17 June 1992
Reply to Chen et al.
Authors: Oliver Pech, Carolin Zippelius
Journal: Endoscopy (2022)

See also: How can we improve our operation?Endoscopy 2022; 54(02): 222-222DOI: 10.1055/a-1690-6518 See also: Diagnostic accuracy of a novel artificial intelligence system for adenoma detection in daily practice: a prospective nonrandomized comparative studyEndoscopy 2022; 54(05): 465-472DOI: 10.1055/a-1556-5984
Below-Knee Amputations
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins
Authors: Thomas Steimlé, Marie-Emilie Dourthe, Marion Alcantara, Aurore Touzart, Mathieu Simonin, Johanna Mondesir, Ludovic Lhermitte, Jonathan Bond, Carlos Graux, Nathalie Grardel, Jean-Michel Cayuela, Isabelle Arnoux, Virginie Gandemer, Marie Balsat, Norbert Vey, Elizabeth Macintyre, Norbert Ifrah, Hervé Dombret, Arnaud Petit, André Baruchel, Philippe Ruminy, Nicolas Boissel, Vahid Asnafi
Journal: Blood Cancer Journal (2022)

Abstract T-cell acute lymphoblastic leukemias (T-ALL) represent 15% of pediatric and 25% of adult ALL. Since they have a particularly poor outcome in relapsed/refractory cases, identifying prognosis factors at diagnosis is crucial to adapting treatment for high-risk patients. Unlike acute myeloid leukemia and BCP ALL, chromosomal rearrangements leading to chimeric fusion-proteins with strong prognosis impact are sparsely reported in T-ALL. To address this issue an RT-MPLA assay was applied to a consecutive series of 522 adult and pediatric T-ALLs and identified a fusion transcript in 20% of cases. PICALM-MLLT10 (4%, n = 23), NUP214-ABL1 (3%, n = 19) and SET-NUP214 (3%, n = 18) were the most frequent. The clinico-biological characteristics linked to fusion transcripts in a subset of 235 patients (138 adults in the GRAALL2003/05 trials and 97 children from the FRALLE2000 trial) were analyzed to identify their prognosis impact. Patients with HOXA trans-deregulated T-ALLs with MLLT10, KMT2A and SET fusion transcripts (17%, 39/235) had a worse prognosis with a 5-year EFS of 35.7% vs 63.7% (HR = 1.63; p = 0.04) and a trend for a higher cumulative incidence of relapse (5-year CIR = 45.7% vs 25.2%, HR = 1.6; p = 0.11). Fusion transcripts status in T-ALL can be robustly identified by RT-MLPA, facilitating risk adapted treatment strategies for high-risk patients.
LETTER FROM NEW YORK.
Authors: None P. B P.
Journal: JAMA (1891)

(FROM OUR OWN CORRESPONDENT.) Experimental Koch Inoculations—Hypodermic Injections of Aniline and Sterilized Oil in the Treatment of Phthisis—The New York County Medical Association—The New York Medico-Legal Society and Hypnotism—American Electro-Therapeutic Society—Miscellaneous Items. While it is, of course, far too soon to judge of the ultimate results of the treatment, the very extended series of experiments with the Koch inoculations which have now been carried on in this city have apparently been attended with effects for the most part corresponding with those reported from Germany. There can be no question, however, that the warning note sent out by Virchow has very properly had the result of making our hospital physicians proceed with marked caution in the matter, and it is probably safe to say that in cases of tubercular meningitis, for instance, the lymph will not again be employed. There appears to be sufficient ground for the belief that pulmonary tuberculosis
Letter: Bartter syndrome
Authors: Neil A. Kurtzman
Journal: JAMA (1976)

<h3>In Reply.—</h3> Drs James and Sutherland were quite correct in pointing out that there may be more than one type of mechanism operative in the pathogenesis of Bartter syndrome. It is also correct that this syndrome is frequently mistakenly ascribed to other disorders. Protracted vomiting, laxative abuse, and persistent diuretic administration may mimic the syndrome. The two patients described in the article by Holland and Preston cited by Dr James may not have had Bartter syndrome. Indeed, the first of these patients was quite sensitive to the pressor effects of angiotensin infusion, an observation that militates against the diagnosis of Bartter syndrome. The observation that plasma volume was increased in some patients said to have Bartter syndrome is most unimpressive. To begin with, the technique is difficult to perform with precision and subject to error; when an error is made, it almost invariably results in plasma volume being overestimated. Second,
Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group
Authors: Olivier Hermine, Xavier Mariette, Raphael Porcher, Matthieu Resche-Rigon, Pierre-Louis Tharaux, Philippe Ravaud
Journal: European Respiratory Journal (2022)

Background Our objective was to determine whether anti-interleukin (IL)-6 receptors improve outcomes of critically ill patients with coronavirus disease 2019 (COVID-19) pneumonia. We report on two cohort-embedded, investigator-initiated, multicentre, open-label, Bayesian randomised controlled clinical trials. Methods Patients were randomly assigned to receive either usual care (UC) or UC+tocilizumab (TCZ) 8 mg·kg −1 (TOCI-2 trial) or UC or UC+sarilumab (SARI) 200 mg (SARI-2 trial), both intravenously on day 1 and, if clinically indicated, on day 3. Results Between 31 March and 20 April 2020, 97 patients were randomised in the TOCI-2 trial, to receive UC (n=46) or UC+TCZ (n=51). At day 14, numbers of patients who did not need noninvasive ventilation (NIV) or mechanical ventilation (MV) and were alive with TCZ or UC were similar (47% versus 42%; median posterior hazard ratio (HR) 1.19, 90% credible interval (CrI) 0.71–2.04), with a posterior probability of HR &gt;1 of 71.4%. Between 27 March and 4 April 2020, 91 patients were randomised in the SARI-2 trial, to receive UC (n=41) or UC+SARI (n=50). At day 14, numbers of patients who did not need NIV or MV and were alive with SARI or UC were similar (38% versus 33%; median posterior HR 1.05, 90% CrI 0.55–2.07), with a posterior probability of HR &gt;1 of 54.9%. Overall, the risk of death up to day 90 was: UC+TCZ 24% versus UC 30% (HR 0.67, 95% CI 0.30–1.49) and UC+SARI 29% versus UC 39% (HR 0.74, 95% CI 0.35–1.58). Both TCZ and SARI increased serious infectious events. Conclusion In critically ill patients with COVID-19, anti-IL-6 receptors did not significantly increase the number of patients alive without any NIV or MV by day 14.